Founded in 2000, Nutra Pharma Corporation operates as a biotechnology company. They specialize in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company also markets several drug products for the treatment of pain under the brands Cobroxin and Nyloxin. Nutra Pharma Corporation has their headquarters in Coral Springs, Florida.
Nutra Pharma, via their subsidiaries, carries out basic drug discovery research and clinical development. They also seek strategic licensing partnerships to reduce the risks associated with the drug development process.
Their Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Cobroxin is available in two formats: a Topical Pain Reliever Gel, and an Oral Pain Reliever Spray. Cobroxin is an all-natural, non-narcotic pain reliever that offers non-addictive pain relief. It is analgesic and anti-inflammatory.
Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. It is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. Nyloxin™ is also offered in an extra strength formula for more advanced (Stage 3) chronic pain.
Both Cobroxin and Nyloxin underwent development by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. The emphasis of ReceptoPharm’s approach to drug discovery and the development of new therapeutic agents are based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra.
ReceptoPharm is also developing proprietary therapeutic protein products. These are primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of their role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through their ISO class 5 and GMP certified facilities.
Nutra Pharma Corporation’s wholly owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits. They are designed to be used for the rapid identification of infectious diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
In March, Nutra Pharma Corporation announced that they received approval from the United States Patent and Trademark Office (USPTO) for their patent describing the use of cobratoxin as a treatment for chronic pain. The patent (US 7,902,152), titled “Use of cobratoxin as an analgesic,” describes a composition of matter for an analgesia and its method of use.
In April, Nutra Pharma Corporation announced that they selected Pentanet CA to serve as the exclusive distributor in Venezuela for the Company’s Nyloxin-branded pain relievers. Penta Corporation is a leading provider of healthcare products, medical and dental instruments as well as surgical equipment for the Venezuelan market.
Nutra Pharma previously announced agreements with distributors in Mexico and Colombia. The drug registration process for Cobroxin® and Nyloxin™ are currently being pursued in more than 20 countries.